Home LiteratureArticle Details
PMID: 18612309 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.

British journal of cancer ·Vol. 99 ·No. 2 ·2008-07-22 ·Pages 364-70

Lesueur F, de Lichy M, Barrois M, Durand G, Bombled J, Avril MF, Chompret A, Boitier F, Lenoir GM, French Familial Melanoma Study Group, Bressac-de Paillerets B, Baccard M, Bachollet B, Berthet P, Bonadona V, Bonnetblanc JM, Caron O, Chevrant-Breton J, Cuny JF, Dalle S, Delaunay M, Demange L, De Quatrebarbes J, Doré JF, Frénay M, Fricker JP, Gauthier-Villars M, Gesta P, Giraud S, Gorry P, Grange F, Green A, Huiart L, Janin N, Joly P, Kérob D, Lasset C, Leroux D, Limacher JM, Longy M, Mansard S, Marrou K, Martin-Denavit T, Mateus C, Maubec E, Olivier-Faivre L, Orlandini V, Pujol P, Sassolas B, Stoppa-Lyonnet D, Thomas L, Vabres P, Venat L, Wierzbicka E, Zattara H

Abstract

Mutations in two genes encoding cell cycle regulatory proteins have been shown to cause familial cutaneous malignant melanoma (CMM). About 20% of melanoma-prone families bear a point mutation in the CDKN2A locus at 9p21, which encodes two unrelated proteins, p16(INK4a) and p14(ARF). Rare mutations in CDK4 have also been linked to the disease. Although the CDKN2A gene has been shown to be the major melanoma predisposing gene, there remains a significant proportion of melanoma kindreds linked to 9p21 in which germline mutations of CDKN2A have not been identified through direct exon sequencing. The purpose of this study was to assess the contribution of large rearrangements in CDKN2A to the disease in melanoma-prone families using multiplex ligation-dependent probe amplification. We examined 214 patients from independent pedigrees with at least two CMM cases. All had been tested for CDKN2A and CDK4 point mutation, and 47 were found positive. Among the remaining 167 negative patients, one carried a novel genomic deletion of CDKN2A exon 2. Overall, genomic deletions represented 2.1% of total mutations in this series (1 of 48), confirming that they explain a very small proportion of CMM susceptibility. In addition, we excluded a new gene on 9p21, KLHL9, as being a major CMM gene.

MeSH Terms
Aged Aged, 80 and over Base Sequence Carrier Proteins/genetics Chromosomes, Human, Pair 9 Cyclin-Dependent Kinase Inhibitor p16/genetics Exons Female Gene Deletion Genes, p16 Genetic Predisposition to Disease Humans Male Melanoma/genetics Middle Aged Molecular Sequence Data Pedigree Point Mutation Reverse Transcriptase Polymerase Chain Reaction Tumor Suppressor Protein p14ARF/genetics
Chemicals
Carrier Proteins Cyclin-Dependent Kinase Inhibitor p16 KLHL6 protein, human Tumor Suppressor Protein p14ARF
Authors & Affiliations
55 authors, click to expand affiliations / ORCID
Lesueur F
Groupe Mélanome, Institut Gustave Roussy, FRE2939 CNRS-Université Paris-Sud, Villejuif, France.
de Lichy M
Barrois M
Durand G
Bombled J
Avril M-F
Chompret A
Boitier F
Lenoir G M
French Familial Melanoma Study Group
Bressac-de Paillerets B
Baccard Monique
Bachollet Bertrand
Berthet Pascaline
Bonadona Valérie
Bonnetblanc Jean-Marie
Caron Olivier
Chevrant-Breton Jacqueline
Cuny Jean-François
Dalle Stéphane
Delaunay Michèle
Demange Liliane
De Quatrebarbes Julie
Doré Jean-François
Frénay Marc
Fricker Jean-Pierre
Gauthier-Villars Marion
Gesta Paul
Giraud Sophie
Gorry Philippe
Grange Florent
Green Andrew
Huiart Laetitia
Janin Nicolas
Joly Pascal
Kérob Delphine
Lasset Christine
Leroux Dominique
Limacher Jean-Marc
Longy Michel
Mansard Sandrine
Marrou Karine
Martin-Denavit Tanguy
Mateus Christine
Maubec Eve
Olivier-Faivre Laurence
Orlandini Vincent
Pujol Pascal
Sassolas Bruno
Stoppa-Lyonnet Dominique
Thomas Luc
Vabres Pierre
Venat Laurence
Wierzbicka Ewa
Zattara Hélène
References (47)
47 references, click to expand
  1. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.
    Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8541-5 PMID: 8710906
  2. The kelch repeat superfamily of proteins: propellers of cell function.
    Trends Cell Biol. 2000 Jan;10(1):17-24 PMID: 10603472
  3. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.
    Nucleic Acids Res. 2002 Jun 15;30(12):e57 PMID: 12060695
  4. Germline epimutation of MLH1 in individuals with multiple cancers.
    Nat Genet. 2004 May;36(5):497-501 PMID: 15064764
  5. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status.
    Cancer Res. 2000 Jan 1;60(1):129-33 PMID: 10646864
  6. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.
    Nat Med. 1995 Jul;1(7):686-92 PMID: 7585152
  7. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred.
    Genes Chromosomes Cancer. 2001 Aug;31(4):398-401 PMID: 11433531
  8. Genetic alterations of the NRP/B gene are associated with human brain tumors.
    Oncogene. 2004 Aug 5;23(35):5890-900 PMID: 15208678
  9. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL.
    Cancer Res. 2006 Oct 15;66(20):9818-28 PMID: 17047042
  10. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
    N Engl J Med. 1995 Oct 12;333(15):970-4 PMID: 7666916
  11. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.
    Nat Genet. 1994 Sep;8(1):23-6 PMID: 7987388
  12. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries.
    Int J Cancer. 2007 Aug 15;121(4):825-31 PMID: 17397031
  13. Retention of the CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma.
    Int J Cancer. 1998 May 4;76(3):312-6 PMID: 9579564
  14. Germline mutations of the CDKN2 gene in UK melanoma families.
    Hum Mol Genet. 1997 Nov;6(12):2061-7 PMID: 9328469
  15. Temperature-sensitive mutants of p16CDKN2 associated with familial melanoma.
    Mol Cell Biol. 1996 Jul;16(7):3844-52 PMID: 8668202
  16. Genetics of melanoma predisposition.
    Oncogene. 2003 May 19;22(20):3053-62 PMID: 12789280
  17. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
    Cancer Res. 2000 Dec 15;60(24):6864-7 PMID: 11156381
  18. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
    J Med Genet. 2006 Jan;43(1):39-47 PMID: 15937071
  19. Identification and characterization of a novel kelch-like gene KLHL15 in silico.
    Oncol Rep. 2005 Jun;13(6):1133-7 PMID: 15870933
  20. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
    Cancer Res. 1998 Jun 1;58(11):2298-303 PMID: 9622062
  21. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.
    Nat Genet. 1996 Jan;12(1):97-9 PMID: 8528263
  22. Inheritance of a cancer-associated MLH1 germ-line epimutation.
    N Engl J Med. 2007 Feb 15;356(7):697-705 PMID: 17301300
  23. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families.
    J Natl Cancer Inst. 2000 Aug 2;92(15):1260-6 PMID: 10922411
  24. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group.
    Hum Mol Genet. 1998 Feb;7(2):209-16 PMID: 9425228
  25. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Eur J Hum Genet. 2003 Apr;11(4):288-96 PMID: 12700603
  26. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Cancer Res. 2007 Apr 15;67(8):3963-9 PMID: 17440112
  27. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation.
    Genes Chromosomes Cancer. 2005 Sep;44(1):10-8 PMID: 15880589
  28. Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer.
    Int J Cancer. 2004 Jul 1;110(4):558-62 PMID: 15122588
  29. New founder germline mutations of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment.
    Genes Chromosomes Cancer. 2007 Aug;46(8):751-60 PMID: 17492760
  30. A single genetic origin for the G101W CDKN2A mutation in 20 melanoma-prone families.
    Am J Hum Genet. 2000 Aug;67(2):311-9 PMID: 10869234
  31. Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma.
    Br J Dermatol. 1998 Jan;138(1):13-21 PMID: 9536218
  32. Familial and attributable risks in cutaneous melanoma: effects of proband and age.
    J Invest Dermatol. 2003 Feb;120(2):217-23 PMID: 12542525
  33. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
    Cancer Lett. 2002 Jun 28;180(2):211-21 PMID: 12175554
  34. Novel CDKN2A mutations detected in western Swedish families with hereditary malignant melanoma.
    J Invest Dermatol. 2007 Jun;127(6):1465-7 PMID: 17255954
  35. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
    Hum Mol Genet. 2001 Jan 1;10(1):55-62 PMID: 11136714
  36. Prevalence of 9p21 deletions in UK melanoma families.
    Genes Chromosomes Cancer. 2005 Nov;44(3):292-300 PMID: 16032697
  37. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    J Natl Cancer Inst. 1997 May 21;89(10):697-702 PMID: 9168184
  38. Comparison between familial and nonfamilial melanoma in France.
    Arch Dermatol. 1995 Oct;131(10):1154-9 PMID: 7574832
  39. Functional, structural, and genetic evaluation of 20 CDKN2A germ line mutations identified in melanoma-prone families or patients.
    Hum Mutat. 2009 Apr;30(4):564-74 PMID: 19260062
  40. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families.
    J Natl Cancer Inst. 2004 May 19;96(10):785-95 PMID: 15150307
  41. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments.
    Hum Mutat. 2002 Sep;20(3):218-26 PMID: 12203994
  42. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Genes Chromosomes Cancer. 2006 Dec;45(12):1155-63 PMID: 17001621
  43. Germline p16 mutations in familial melanoma.
    Nat Genet. 1994 Sep;8(1):15-21 PMID: 7987387
  44. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity.
    Am J Hum Genet. 1993 Mar;52(3):537-50 PMID: 8447320
  45. Localization of a novel melanoma susceptibility locus to 1p22.
    Am J Hum Genet. 2003 Aug;73(2):301-13 PMID: 12844286
  46. Low frequency of p16/CDKN2A methylation in sporadic melanoma: comparative approaches for methylation analysis of primary tumors.
    Cancer Res. 1997 Dec 1;57(23):5336-47 PMID: 9393758
  47. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands.
    J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8 PMID: 7932824
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
1532-1827
Published
2008-07-22
Epub
2008-00-08
Pages
364-70
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2480975
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com